Jan. 31, 2025 – The FDA has approved Symbravo, a new migraine medication that combines two powerful ingredients—rizatriptan and meloxicam—to quickly relieve migraine pain. Symbravo is designed for adults with migraines, whether or not they experience aura (visual disturbances).
In clinical trials, a single dose helped many patients get rid of migraine pain and return to normal activities within two hours. The relief lasted up to 48 hours without needing additional medication, according to Axsome Therapeutics, the company that makes Symbravo.
More than 21,000 migraine attacks were treated in studies, showing that Symbravo works whether taken at the first sign of mild pain or later when the pain is more severe.
The company expects Symbravo to be available in about four months.
The drug is not intended to prevent or decrease the number of migraine headaches, or to treat hemiplegic or basilar migraine or cluster headache. It is not approved for use in children.
According to the American Migraine Foundation, more than 39 million Americans suffer from migraine, which is the leading cause of disability among neurological disorders in the United States.
